Dermatologie

Références1. Mulder WM, Meinardi MM, Bruynzeel DP. Huidreacties door geneesmiddelen. Ned TijdschrGeneeskd 2004;148:415-20.2. Gielen K, Goossens A. Contactallergische reacties bij medisch personeel door geneesmiddelen.Tijdschr Geneeskd 2004;60:1776-84.3. NICE. Frequency of application of topical corticosteroids for atopic eczema. Technology Appraisal 81- August 2004.4. Prodigy Guidance. Dermatitis – contact. Oct 2005. www.prodigy.nhs.uk5. Saary J, Qureshi R, Palda V et al. A systematic review of contact dermatitis treatment andprevention. J Am Acad Dermatol 2005;53:845-55.6. Anonymous. Topical steroids for atopic dermatitis in primary care. Drug Ther Bull 2003;41:5-8.7. Anonymous. Atopic eczema in primary care. MeReC Bulletin NHS 2004;14:1-4.http://www.npc.co.uk/MeReC_Bulletins/2003Volumes/Vol14no1.pdf8. Williams H, Bigby M, Diepgen T et al. Evidence Based Dermatology. BMJ Books. April 2003.9. Dermatocorticosteroïden. Farmacotherapeutisch Kompas 2006, p. 568-74. www.fk.cvz.nl.10. Green C, Colquitt J, Kirby J et al. Clinical and cost-effectiveness of once-daily versus more frequentuse of same potency topical corticosteroids for atopic eczema: a systematic review and economicevaluation. Health Technology Assessment 2004;8(47).11. Anonymous. Tacrolimus dermique: trop d’inconnues pour utiliser cet immunosuppresseur par voiecutanée. La Revue Prescrire 2003;23:805-9.12. Ashcroft D, Dimmock P, Garside R et al. Efficacy and tolerability of topical pimecrolimus andtacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ2005;330:516-22.13. Garside R, Stein K, Castelnuovo E et al. The effectiveness and cost-effectiveness of pimecrolimusand tacrolimus for topic eczema: a systematic review and economic evaluation. Health TechnologyAssessment 2005;9(29).14. Anonymous. Pimécrolimus ou tacrolimus dermique et cancer. Revue Prescrire 2005;264:59215. CHMP safety review of tacrolimus ointment and pimecrolimus cream.http://www.emea.europa.eu/pdfs/general/direct/pr/9888206en.pdf16. Anonymous. Pimecrolimus. Aust Presc 2003;26:149-50.17. NGC. Tacrolimus and pimecrolimus for atopic eczema. NGC October 6, 2005 www.guideline.gov18. NICE. Tacrolimus an pimecrolimus for atopic eczema. Technology Appraisal 82 - august 2004)http://www.australianprescriber.com/magazine/26/6/146/51/19. Manriquez JJ, Uribe P.. Seborrhoeic dermatitis. BMJ Clinical Evidence [online] 2006 [cited Dec 20].www.clinicalevidence.com20. Prodigy Guidance. Seborrhoeic dermatitis. July 2006. www.prodigy.nhs.uk21. Van Zuuren E, Graber M, Hollis S et al. Interventions for rosacea. The Cochrane Database ofSystematic Reviews 2005, Issue 3. Art. No.: CD003262. DOI: 10.1002/14651858.CD003262.pub3.22. Anonymous. De behandeling van rosacea. Geneesmiddelenbulletin 1998;32:101-5.www.geneesmiddelenbulletin.nl23. Prodigy Guidance. Rosacea. July 2005. www.prodigy.nhs.uk24. Bigby M, Gibbs S.. Warts. . BMJ Clinical Evidence [online] 2006 [cited Dec 20].www.clinicalevidence.com25. George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J GenPract 2003;53:480-7.26. Koning S, Verhagen A, van Suijlekom-Smit L et al. Interventions for impetigo. The CochraneDatabase of Systematic Reviews 2003, Issue 2. Art. No.: CD003261.pub2. DOI:10.1002/14651858.CD003261.pub2.27. HPA Management of infection guidance for primary care for consultation & local adaptation. HealthProtection Agency. www.hpa.org.uk geraadpleegd op 20/12/06.28. Bacteriële huidinfecties. Farmacotherapeutisch Kompas 2006; www.fk.cvz.nl29. Middelen bij wondbehandeling en desinfectie van de huid. Farmacotherapeutisch Kompas 2006,p.609-14; www.fk.cvz.nl30. Martindale. The Complete Drug Reference (Book with CD-ROM), 34th Edition by Sean C.Sweetman.31. Boukes F, Van der Burgh J, Nijman F et al. NHG-Standaard Bacteriële Huidinfecties. Huisarts Wet1998;41:427-37. http://nhg.artsennet.nl/upload/104/standaarden/M68/start.htm32. Laube S, Farrell A. Bacterial skin infections in the elderly: diagnosis and treatment. Drugs Aging2002;19:331-42.426 Dermatologie